What To Say About Personalized Depression Treatment To Your Mom > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medication are ineffective. A customized treatment may be the answer.

Cue is a digital intervention platform that translates passively acquired normal smartphone sensor data into personalized micro-interventions to improve mental health. We looked at the best-fitting personal ML models to each subject using Shapley values, in order to understand their characteristic predictors. This revealed distinct features that changed mood in a predictable manner over time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 However, only about half of those suffering from the condition receive treatment1. To improve the outcomes, doctors must be able to recognize and treat patients with the highest probability of responding to specific treatments.

The treatment of depression can be personalized to help. By using mobile phone sensors as well as an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from the treatments they receive. With two grants awarded totaling over $10 million, they will make use of these techniques to determine the biological and behavioral factors that determine responses to antidepressant medications as well as psychotherapy.

So far, the majority of research on predictors for depression treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, sex and educational level, clinical characteristics like the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

Very few studies have used longitudinal data to predict mood of individuals. Few studies also consider the fact that moods can differ significantly between individuals. Therefore, it is crucial to devise methods that allow for the analysis and measurement of individual differences in mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to identify patterns of behaviour and emotions that are unique to each individual.

The team also developed a machine learning algorithm to create dynamic predictors for each person's mood for depression treatment free. The algorithm blends the individual differences to produce a unique "digital genotype" for each participant.

This digital phenotype has been correlated with CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak however (Pearson r = 0,08, BH adjusted P-value 3.55 x 10 03) and varied significantly among individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1 but is often underdiagnosed and undertreated2. In addition the absence of effective treatments and stigmatization associated with depressive disorders prevent many people from seeking help.

To aid in the development of a personalized treatment, it is important to identify the factors that predict symptoms. However, the methods used to predict symptoms depend on the clinical interview which is unreliable and only detects a tiny number of symptoms related to depression.2

Machine learning can enhance the accuracy of the diagnosis and natural treatment for anxiety and depression of depression by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to provide a wide range of distinct actions and behaviors that are difficult to document through interviews and permit continuous and high-resolution measurements.

The study involved University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and depression treatment without medication program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or to clinical treatment depending on the severity of their depression. Participants who scored a high on the CAT DI of 35 or 65 students were assigned online support by an instructor and those with scores of 75 patients were referred to in-person psychotherapy.

Participants were asked a set of questions at the beginning of the study about their demographics and psychosocial characteristics. The questions covered age, sex and education as well as marital status, financial status, whether they were divorced or not, current suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. Participants also rated their level of depression severity on a scale ranging from 0-100 using the CAT-DI. The CAT-DI test was conducted every two weeks for participants who received online support, and weekly for those who received in-person care.

Predictors of Treatment Reaction

Research is focusing on personalization of depression treatment. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective medications for each person. Particularly, pharmacogenetics can identify genetic variations that affect how the body metabolizes antidepressants. This allows doctors to select medications that are likely to be most effective for each patient, reducing the time and effort required in trial-and-error procedures and avoiding side effects that might otherwise slow progress.

Another approach that is promising is to build models of prediction using a variety of data sources, combining data from clinical studies and neural imaging data. These models can be used to identify the variables that are most predictive of a particular outcome, such as whether a medication can improve mood or symptoms. These models can be used to determine the patient's response to a treatment, which will help doctors to maximize the effectiveness.

A new era of research utilizes machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables to improve predictive accuracy. These models have proven to be useful for forecasting treatment outcomes, such as the response to antidepressants. These techniques are becoming increasingly popular in psychiatry and could become the norm in the future treatment.

In addition to prediction models based on ML The study of the underlying mechanisms of depression is continuing. Recent research suggests that the disorder is associated with neural dysfunctions that affect specific circuits. This suggests that the treatment for depression will be individualized based on targeted therapies that target these circuits in order to restore normal function.

Internet-based interventions are a way to achieve this. They can provide a more tailored and individualized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality life for MDD patients. Furthermore, a randomized controlled study of a personalised treatment for depression demonstrated steady improvement and decreased adverse effects in a large proportion of participants.

Predictors of adverse effects

In the treatment of depression, a major challenge is predicting and determining the antidepressant that will cause very little or no negative side negative effects. Many patients are prescribed a variety of medications before finding a medication that is safe and effective. Pharmacogenetics is an exciting new avenue for a more effective and precise approach to choosing antidepressant medications.

A variety of predictors are available to determine which antidepressant is best to prescribe, such as gene variants, patient phenotypes (e.g. gender, sex or ethnicity) and co-morbidities. To identify the most reliable and accurate predictors of a specific treatment, randomized controlled trials with larger samples will be required. This is due to the fact that the identification of interaction effects or moderators could be more difficult in trials that focus on a single instance of treatment per patient instead of multiple sessions of treatment over time.

Additionally, predicting a patient's response will likely require information about the comorbidities, symptoms profiles and the patient's own perception of effectiveness and tolerability. Currently, only a few easily identifiable sociodemographic variables and clinical variables are reliable in predicting the response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

Many issues remain to be resolved in the use of pharmacogenetics for depression treatment. First is a thorough understanding of the genetic mechanisms is needed and an understanding of what constitutes a reliable predictor for treatment response. In addition, ethical issues like privacy and the appropriate use of personal genetic information should be considered with care. The use of pharmacogenetics may, in the long run, reduce stigma surrounding mental health treatments and improve the outcomes of natural treatment for depression. But, like any other psychiatric treatment, careful consideration and implementation is required. At present, the most effective method is to offer patients a variety of effective depression medications and encourage them to speak freely with their doctors about their concerns and experiences.